Current Issue


VOL 14 NO 1 • Jan/Feb 2023


This issue’s cover illustration depicts the mechanism of action of luspatercept. Luspatercept (cyan) is a recombinant fusion protein shown binding with transforming growth factor-beta ligands (TGF-β orange shape) rather than the ALK- receptor (blue receptor in lipid bilayer) and reduces SMAD2 and SMAD3 signaling, resulting in erythroid maturation. Artwork by Alexandra Webber © 2023, DNA Illustrations, Inc., Asheville, North Carolina.


Editorial

Oncology Advanced Practice Posters: New Research and Insights Into Our Future

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO

Presenting a poster at a conference is an important way for us as advanced practitioners to showcase our work, receive feedback, and affect future directions in the way we care for our patients. Conversely, as an attendee, I am always inspired by the work of my colleagues and energized to find ne...


Research and Scholarship

Predictors of Nurse Practitioner Prescription of Opioids for Cancer Pain: Quantitative Results

Erin McMenamin,(1,2) PhD, CRNP, Marye Kellermann,(3) PhD, CRNP, FAANP, Regina Cunningham,(1,2) PhD, FAAN, and Janet Selway,(3) DNSc, AGNP-C, CPNP-PC, FAANP

The nurse practitioner (NP) role has evolved over time within the health-care workforce. The addition of prescriptive privileges for NPs has led to greater role independence. Nurse practitioners have the ability to prescribe controlled substances in all states (American Association of Nurse Pract...


Research and Scholarship

Serious Illness Conversation Training for Inpatient Medical Oncology Advanced Practice Providers: A Quality Improvement Project

Jo Clarke, DNP, ANP-BC, NP-C, ACNP-BC, APRN-CNP, AOCNP®, Mary Alice Momeyer, DNP, APRN-CNP, Robin Rosselet, DNP, RN, APRN-CNP, AOCN®, Loraine Sinnott, PhD, and Janine Overcash, PhD, APRN-CNP, FAANP, FAAN

The American Cancer Society estimated in 2022 there would be 1.9 million new cancer cases, 609,360 cancer deaths, and 18 million cancer survivors in the United States (National Cancer Institute, 2022). These large numbers reflect the magnitude of people living with cancer. The primary site for 70...


Research and Scholarship

Interventions to Improve Advanced Practitioner Work-Related Quality of Life and Patient Satisfaction

Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, Olivia West, MSN, AG-ACNP-BC, Annie Austin, MSN, AGACNP-BC, AOCNP®, and Karline Peal, MBA, RTT

Nurse practitioners (NPs) and physician assistants (PAs) serve a critical role in the care of hospitalized patients with cancer. Given the rising demand for cancer treatments and shortage of physicians within the United States, NPs and PAs are well positioned to meet patient needs (Yang et al., 2...


Review Article

The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials

Ly Dsouza, PA-C, MPAS

In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective therapy for patients with refractory lymphoma and myeloma. To date, six CAR T-cell therapies have been approved by the US Food and Drug Administration (FDA) for this patient population (Table 1). These app...


Grand Rounds

Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?

James A. Davis, PharmD, BCOP, Abigail Shockley, PharmD, Amanda Herbst, PA-C, and Lindsey Hendrickson, DNP, APRN, FNP-C

Case Study Mr. D is a well-educated 71-year-old male who presents to clinic with complaints of an enlarging neck mass, general malaise, and fatigue. A core needle biopsy is performed that reveals a diagnosis of non-germinal center B-cell diffuse large B-cell lymphoma. A subsequent PET scan reveal...


Practice Matters

Advanced Practice Provider Model for Urgent Oncology Care

Marie Iannelli, MSN, CRNP, Alexis Brimm-Akins, MSN, CRNP, Anessa M. Foxwell, MSN, CRNP ACHPN, Beth Sandy, MSN, CRNP, Krista Winalski, BSN, RN, OCN®, Kara Gatto, BSN, RN, Suzanne McGettigan, MSN, CRNP, AOCN®, and Carolyn Grande, MSN, CRNP, AOCNP®

There was an estimated 1.9 million cancer cases diagnosed and 609,360 cancer-related deaths in 2022 in the United States (American Cancer Society, 2022). Cancer treatment advances have expanded through the years to more complex regimens and novel therapies with diverse mechanisms of action and un...


Prescriber's Corner

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes

Sara M. Tinsley-Vance,(1) PhD, APRN, AOCN®, Mark Davis,(2) MPAS, PA-C, and Olalekan Ajayi,(3) PharmD, MBA

Myelodysplastic syndromes (MDS) are a group of malignant stem cell disorders characterized by clonal hematopoiesis, cytopenias (anemia, neutropenia, and/or thrombocytopenia), and progression to acute myeloid leukemia in approximately 20% of cases (Falantes et al., 2018; Pereira et al., 2011). App...


Diagnostic Snapshot

Indeterminate Thyroid Nodules: When to Worry?

Amanda Tibbels, MPAS, PA-C

History Mrs. C is a 56-year-old woman with a history of depression, anxiety, and kidney stones, and was diagnosed with multiple thyroid nodules in February 2020. She was seeing a local endocrinologist for abnormal thyroid function tests when the endocrinologist palpated the nodules on physical ex...


Meeting Report

Clinical Posters From JADPRO Live 2022


JL1001C: A Bone Marrow Aspirate and Biopsy Educational Program for Advanced Practice Providers Utilizing Task Trainers Jessica Casselberry, DNP, ANP-BC, AOCNP, Glen J. Peterson, RN, DNP, ACNP, Jessica Zucker, MSN, AGNP-BC; University of Colorado, School of Medicine, Division of Hematology Backgro...


Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2023 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.